|
Title
|
Status
|
|
|
Recruiting
in 4 of 4 locations
|
|
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer
growth in different ways. Some block the ability of cancer cells to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them.
Lenalidomide may stimulate the immune system in different ways and stop cancer cells from
growing. Giving fludarabine and rituximab together with lenalidomide or cyclophosphamide may
kill more cancer cells.
PURPOSE: This randomized phase II trial is studying fludarabine and rituximab to compare how
well they work with or without lenalidomide or cyclophosphamide in treating patients with
symptomatic chronic lymphocytic leukemia.
|
|
|
Recruiting
in 3 of 4 locations
|
|
The purpose of this study is to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia.
|
|
|
Recruiting
in 2 of 2 locations
|
|
The purpose of this study is to determine the safety and effectiveness of different dose
regimen of lenalidomide in patients with relapsed or refractory chronic lymphocytic
leukemia.
|
|
|
Recruiting
in 1 of 2 locations
|
|
AEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase 1 trials and merits further evaluation in this disease. This trial is designed to determine the recommended dose of AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and indolent B-cell lymphomas.
|
|
|
Recruiting
in 1 of 1 locations
|
|
OBJECTIVES
To investigate:
- the mechanism of Valproic Acid (VPA)-induced apoptosis in B-CLL
- the ability of VPA in combination with standard chemotherapy or new antitumor agents to
induce a synergistic antitumor effect in chronic lymphocytic leukemia (CLL) cells
- the clinical efficacy of VPA in previously treated CLL patients.
This will be an example of a translational research study where the results of our
laboratory studies will be applied to a clinical trial in the CLL clinic at CancerCare
Manitoba.
|
|
|
Pending
in 4 of 4 locations
|
|
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of RO5072759
in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil
alone in patients with previously untreated chronic lymphocytic leukemia. Patients will be
randomized to receive a maximum of 6 cycles of either RO5072759 (1000mg iv infusion, on days
1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5mg/kg orally, days 1
and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375mg/m2 cycle 1, 500mg/m2 cycles
2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is >6
months and follow-up for disease-progression and safety will be at least 5 years. In the US,
this trial is sponsored/managed by Genentech.
|
|
|
Recruiting
in 1 of 1 locations
|
|
This is a phase II, non-randomized, single institution study in symptomatic, previously untreated CLL patients. All patients will receive the study drug, lenalidomide, given PO daily continuously on a 28 day cycle at the starting dose level of either 2.5 mgs or 5 mgs with dose escalations to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle. Patients will be treated with lenalidomide and dexamethasone to 2 cycles past CR or to a maximum of 18 cycles. Primary endpoint is response.
|
|
|
Recruiting
in 2 of 2 locations
|
|
The purpose of this study is to determine the safety and efficacy of lenalidomide as a first
line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will
compare the effects (good and bad) of lenalidomide with chlorambucil.
|
|
|
Recruiting
in 1 of 1 locations
|
|
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies
|
|
|
Recruiting
in 6 of 6 locations
|
|
RATIONALE: Giving chemotherapy before a donor peripheral stem cell transplant or bone marrow
transplant using stem cells from a brother or sister that closely match the patient's stem
cells, helps stop the growth of cancer or abnormal cells. It also helps stop the patient's
immune system from rejecting the donor's stem cells. The donated stem cells may replace the
patient's immune cells and help destroy any remaining cancer or abnormal cells
(graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
immune response against the body's normal cells. Giving colony-stimulating factors, such as
G-CSF, to the donor helps the stem cells move from the bone marrow to the blood so they can
be collected and stored. Giving methotrexate and cyclosporine before and after transplant
may stop this from happening. It is not yet known whether a donor peripheral stem cell
transplant is more effective than a donor bone marrow transplant in treating hematologic
cancers or other diseases.
PURPOSE: This randomized phase III trial is studying filgrastim-mobilized sibling donor
peripheral stem cell transplant to see how well it works compared with sibling donor bone
marrow transplant in treating patients with hematologic cancers or other diseases.
|
